Quick Answer: GLP-1 receptor agonists do not directly cause vision problems, but may worsen diabetic retinopathy in patients with pre-existing eye disease who experience rapid blood glucose improvements
These trends are similar worldwide, as shown by a recent study demonstrating only two of fifteen countries surveyed had adequate access to neuro-ophthalmology [4]
Tirzepatide constipation tends to follow similar patterns and responds to the same interventions
Incretin-based drugs are now being investigated and in some cases approved for a wide range of conditions, including cardiovascular disease, neurodegenerative disorders, and even substance use disorder
8 SUMMIT also demonstrated significant improvements in patient-reported outcomes: at 52 weeks, tirzepatide increased KCCQ-CSS, with a between-group mean difference of 6.9 points, and increased 6-minute walk distance, with a between-group mean difference of 18.3 m